Logo image
The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-β2
Journal article   Open access   Peer reviewed

The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-β2

F Arslan, A-K Bosserhoff, T Nickl-Jockschat, A Doerfelt, U Bogdahn and P Hau
British journal of cancer, Vol.96(10), pp.1560-1568
05/21/2007
DOI: 10.1038/sj.bjc.6603766
PMCID: PMC2359935
PMID: 17453002
url
https://doi.org/10.1038/sj.bjc.6603766View
Published (Version of record) Open Access

Abstract

Versican is a large chondroitin sulphate proteoglycan produced by several tumour cell types, including high-grade glioma. The increased expression of certain versican isoforms in the extracellular matrix (ECM) plays a role in tumour cell growth, adhesion and migration. Transforming growth factor- β 2 (TGF- β 2) is an important modulator of glioma invasion, partially by remodeling the ECM. However, it is unknown whether it interacts with versican during malignant progression of glioma cells. Here, we analysed the effect of TGF- β 2 on the expression of versican isoforms. The expression of versican V0/V1 was upregulated by TGF- β 2 detected by quantitative polymerase chain reaction and immunoprecipitation, whereas V2 was not induced. Using time-lapse scratch and spheroid migration assays, we observed that the glioma migration rate is significantly increased by exogenous TGF- β 2 and inhibited by TGF- β 2-specific antisense oligonucleotides. Interestingly, an antibody specific for the DPEAAE region of glycosaminoglycan- β domain of versican was able to reverse the effect of TGF- β 2 on glioma migration in a dose-dependent manner. Taken together, we report here that TGF- β 2 triggers the malignant phenotype of high-grade gliomas by induction of migration, and that this effect is, at least in part, mediated by versican V0/V1.
migration TGF-β Molecular Diagnostics high-grade glioma Versican

Details

Metrics

Logo image